Introduction
The ongoing increase in heart failure (HF) in the population urges new treatment options. Currently available therapeutic strategies, including optimal medical therapy, implantable devices (cardioverter-defibrillators, cardiac resynchronization therapy, left ventricle assist devices), and heart transplantation are insufficient. The only definitive treatment of HF (i.e. heart transplantation) is limited by an extremely low number of donor hearts, the necessity for immunosuppression and restrictive inclusion criteria. However, there is great clinical enthusiasm for left ventricle assist devices. Owing to technological advances they have became smaller and more effective; however, they are expensive, complicated, and may not be suitable for patients with co-morbidities and in older age. Therefore, myocardial regeneration involving delivery of stem cells or regenerative agents into the myocardium remains in the scope of interest of many research teams worldwide. To date, a range of cells has been investigated starting with skeletal myoblasts, through a variety of blood precursor cells, including the experience of our team, 1 ending up with cardiac stem cells most recently. 2, 3 Nevertheless, the autologous muscle-derived stem cells continue to be an interesting source of cells because of their contractile function, easy collection from the skeletal muscle, rapid proliferation, and resistance to ischaemic conditions. Skeletal myoblasts were first studied in early 2000 and the study of Menasché et al. 4 was followed by series of clinical trials. Predominantly, cells were administered during cardiac surgery 5 -9 or with left ventricle assist device implantation. 10 The most recent studies used percutaneous transcatheter approach.
11 -17 The initial enthusiasm for these cells was cooled by their unsatisfactory incorporation to the myocardium and suspected arrhythmogenic potential. The latter may largely result from electrical isolation of grafted cells owing to the loss of gap junctions in the mature skeletal myotubes and an electromechanical coupling pattern that differs from that of cardiomyocytes. 18 It seems that genetic modification of myoblasts could help overcoming these issues. Different strategies leading to overexpression of connexin-43 (Cx-43) in the myoblasts has been studied previously. 19, 20 In vitro experience with rats has shown enhanced electrical coupling between skeletal myoblasts owing overexpression of Cx-43. 21 In mice, myoblasts genetically modified to express Cx-43 showed in vivo better protection against induced ventricular tachycardia compared with naïve cells. 22 The potential usefulness of human skeletal myoblasts transfected with the Cx-43 gene for myocardial regeneration has also been documented in the preclinical studies of the murine infarction model. 23 Based on these studies we designed this pilot clinical trial to evaluate the effectiveness and safety of Cx-43-modified myoblasts for the treatment of patients with advanced HF, mostly from 'non option' group.
Methods Objective
This pilot clinical phase I prospective study aimed to evaluate the safety, feasibility and effectiveness of Cx-43-modified muscle-derived stem/progenitor cells (MDS/PCs) for the regeneration of failing myocardium. 
Study group
Subjects were eligible if meeting all of the following criteria: (i) chronic HF at a New York Heart Association (NYHA) functional class between II and IV; (ii) implanted cardioverter-defibrillator (ICD) or cardiac resynchronization therapy device with defibrillation option (CRT-D); (iii) echocardiographic evidence of left ventricular (LV) systolic dysfunction with ejection fraction ≤40%; (iv) subjects ineligible or disagreeing to invasive interventions, including coronary angioplasty or cardiac surgery, or subjects being regular candidates for heart transplantation or ineligible for transplantation (i.e. 'no option group'); (v) up-to-date optimal therapy of HF 24 and ischaemic heart disease (if applicable) for at least 3 months before enrolment.
The exclusion criteria were: (i) unstable coronary artery disease, acute decompensation of HF or coronary intervention within 30 days of enrolment; (ii) significant coagulopathy; (iii) severe renal failure (estimated glomerular filtration rate < 30 ml/min.1.73 m 2 ) or significant abnormalities of liver function (aspartate or alanine transaminases above five times the upper limit of normal); (iv) hepatitis type B or C or human immunodeficiency virus (HIV) infection; (v) severe mitral or aortic valve disease or presence of aortic prosthetic valve; (vi) LV wall thickness <6 mm or LV thrombus; (vii) known co-morbidities that could have a significant impact on prognosis, including active malignant diseases or active autoimmune disease; (viii) lack of informed consent or life expectancy less than 12 months.
All study procedures were administered after the participants read and understood the patient information sheet and signed the informed consent forms. The study protocol was approved by the Ethics Committee of the Poznan University of Medical Sciences (nos. 753/11 and 1030/12). The study was carried out in accordance with the Declaration of Helsinki.
Study procedures

Harvesting muscle biopsy
Approximately, 1 cm 3 of skeletal muscle biopsy was harvested by a surgeon from the femoral quadriceps muscle under local anaesthesia in aseptic conditions. It was immediately immersed in a dedicated medium and transferred to the Institute of Human Genetics, Polish Academy of Sciences in Poznan for further handling cell culture and genetic modification.
In vitro myoblast culture and transfection evaluation
The MDS/PCs were isolated from the provided biopsies. After mechanical dissection, the tissue was subjected to digestion with 0.02% collagenase solution (Sigma-Aldrich, St. Louis, MO, USA). In brief, the obtained cell suspension was filtered through an 80 μm mesh, centrifuged and plated on a gelatin-covered culture dish. The myoblasts were cultured with 4.5 g/L of glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented with 20% fetal bovine serum, 1% GlutaMAX, 1% Chick Embryo Extract (Seralab, West Sussex, UK), 1% antibiotic and antimycotic solution (Life Technologies, Carlsbad, CA, USA) and basic fibroblast growth factor (Sigma-Aldrich) maintained in standard in vitro conditions: 5% CO 2 , 37 ∘ C and 95% humidity. To achieve large-scale cell cultures, the myoblasts were passaged every 4-5 days while the medium was replaced every other day. After reaching the 300-600 × 10 6 cells (after 4-5 weeks), the cells were transfected with pCiNeo plasmid (Promega, Fitchburg, WI, USA) containing the coding sequence for the Cx-43 gene (GJA1, NM_000165.3) using electroporation by Gene Pulser Xcell Total System (Bio-Rad, Hercules, CA, USA). The coding sequence of Cx-43 was amplified using commercially available human heart RNA (Life Technologies) and primers included sequences recognized by BamHI and XhoI restriction enzymes. The cDNA of Cx-43 was then cloned into the pCiNeo vector. To determine the efficiency of transfection process, we used the pEGFP-C1 (Clonetech, Mountain View, CA, USA) plasmid, which contains the sequences of green fluorescent protein. Each 10 7 cell sample was resuspended in a final volume of 200 μL of F10 medium in cuvettes with 0.2 cm gap and transfected with 53 μg of plasmids (one pulse, wave tension 160 V over 15 ms). The medium was replaced at 24 h after electroporation and on the next day the myoblast culture was completed and a proportion of the myoblasts were examined in order to: (i) determine the number of cells; (ii) determine CD56 expression by flow cytometer; (iii) analyse number of apoptotic cells using the Annexin V-fluorescein isothiocyanate test by flow cytometer; (iv) determine Cx-43 expression at mRNA level using real-time polymerase chain reaction. Before the cells were dispensed for implantation they were washed several times in DMEM medium without Phenol Red and then resuspended in 3 mL of 0.9% NaCl solution containing 1% human serum albumin.
Injection procedure
The injection procedure was performed at the Cardiac Electrophysiology Laboratory of the 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. After puncturing the right femoral artery and inserting a vascular sheath, the subjects were given systemic anticoagulation with intravenous unfractionated heparin at a dose of 80 IU/kg of body weight, followed by additional injections targeting activated clotting time between 250 and 300 s. Subsequently, a NogaStar ® (Biologics Delivery Systems, Johnson & Johnson Co, Irvindale, CA, USA) mapping catheter was inserted transaortically into the left ventricle. The LV mapping included collection of at least key 10 points per segment meeting the criteria and equally distributed in each of 9 anatomical segments of the left ventricle (apical, medial and basal segments of septal, anterior, posterior and lateral walls). The acquired points were accepted if there was no ST elevation in the unipolar recordings and local stability was ≤3.5 mm. The final LV volume and infarcted/affected zones were verified with echocardiography. Simultaneously, the cell suspension was prepared and aseptically divided into the dedicated 1-mL sterile syringes. The procedure of transendocardial injection of the cellular suspension was carried out using a NOGA ® MyoStar ® (Biologics Delivery Systems, Johnson & Johnson Co, Irvindale, CA, USA) intramyocardial injection catheter that was prepared as per the manufacturer's instructions. All subjects were given 300 mg amiodarone intravenously during the injection procedure. The target injection sites were selected if they met all of the following criteria: unipolar amplitude >5.0 mV, local loop shortening (LLS) <6%, loop stability (LS) <4 mm, no significant ST elevation in the unipolar signal, and distance between points >8 mm. The injection site was considered optimal if ventricular ectopic beat was observed upon needle ejection and stable needle anchoring was confirmed under fluoroscopy. Each injection volume was approximately 0.2 mL and injection duration was approximately 30 s followed by a 5 s countdown before needle withdrawal. Continuous monitoring of vital signs was carried out during the procedure. Upon completion of the procedure, all subjects underwent point-of-care echocardiography in order to check for any acute complications. In addition, they were monitored for next 24 h for possible arrhythmic events and puncture site bleeding. 
Clinical evaluation and follow-up
All subjects underwent clinical evaluation at baseline, after the procedure, and at month 6. The clinical evaluation included physical examination, laboratory tests, cardiopulmonary exercise test, and echocardiography. After the index procedure the participants stayed at hospital for the next 3 days and were followed up for at least 6 months. In addition to clinical evaluation, a safety assessment included ICD interrogation for the presence of significant ventricular arrhythmia and was carried out at baseline and at months 3 and 6. A telephone survey was also conducted after 1 month of the procedure to identify any adverse events. Moreover, an invasive endocardial electromechanical assessment of the left ventricle was carried out using the NOGA XP system after 6 months in order to assess for possible changes of myocardial viability, contractility, and volumes.
All patients carried out a maximal, symptom-limited (fatigue and/or dyspnoea) treadmill exercise test according to the modified Bruce protocol (standard Bruce protocol plus initial stage 0-3 min, 1.7 km/h, on a 5% incline). Patients were encouraged to continue for as long as their respiratory quotient exceeded 1. The peak oxygen consumption, carbon dioxide production (VCO 2 ), and minute ventilation (VE) were measured using breath by breath gas analysis (Vmax29; Sensor Medics, Yorba Linda, CA, USA). Before each test the system was calibrated with a standard gas mixture of predefined concentrations. A standard 12-lead electrocardiogram was continuously recorded. Blood pressure was measured every 2 min using a cuff sphygmomanometer. Peak oxygen consumption was defined as a mean of values measured within the last 20 s of exercise, and expressed as both mL/kg.min and mL/min, and as the percentage of predicted peak oxygen consumption. The ventilation/carbon dioxide slope (VE/VCO 2 slope) was calculated automatically by Vmax29 software.
Standard transthoracic echocardiography was performed at baseline, after the procedure, on the discharge day and after 6 months. All measures were carried out by an experienced echocardiographer blinded to the study treatment.
Study endpoints
The safety analysis included the following endpoints: occurrence of all-cause death or cardiovascular death, presence of sustained ventricular tachycardia (>120 b.p.m.) or ventricular fibrillation requiring ICD therapy, and presence of procedure-related adverse events.
The efficacy analysis included the following endpoints: change from baseline of LV ejection fraction (LVEF), LV end-diastolic and end-systolic volumes by echocardiography, change from baseline of LV viability and mobility by electro-anatomical assessment, and change from baseline of exercise capacity by cardiopulmonary exercise test.
Statistical analysis
The analysis and comparison of endomyocardial maps involved segmentation of the left ventricle into nine segments (apical, medial, and basal segments of septal, anterior, posterior, and lateral walls) using the NOGA XP built-in software.
The data were presented as means and standard deviations. The Shapiro-Wilk test was used to verify normal distribution of the data. The comparisons of parameters between the baseline and after 6 months of follow-up were performed using a Student's t-test for paired data or, alternatively, the Wilcoxon matched test. Statistical analysis was performed with the use of the Statistica 10 (StatSoft, Statistica, Tulsa, OK, USA) software. All tests were considered significant at P < 0.05. 
Results
Characteristics of the cell population
The mean duration of cellular culture was 36 ± 12 days. The mean total number of cultured cells was 552. 
Clinical characteristics
A total of 13 subjects were enrolled in the study but one did not agree to undergo a follow-up electro-anatomical mapping (Figure 2) . The baseline characteristics of the study participants are displayed in Table 1 . The injection of MDS/PCs was associated with a significant improvement of exercise capacity (i.e. NYHA functional class and exercise duration, after 6-month follow-up). Oxygen consumption and oxygen pulse were significantly better after 6 months of the cell delivery procedure, as measured by the cardiopulmonary exercise test. No significant differences were documented for LVEF and LV end-diastolic volume, although there was a tendency towards some improvement. There was also a trend towards lower BNP levels, 
Electro-anatomical assessment
The follow-up electro-anatomical mapping was performed in 12 of the 13 patients injected. There was a significant increase in mean total unipolar voltages 6 months after the index procedure (8.83 ± 2.80 vs. 10.22 ± 3.41 mV, P = 0.041). The mean total bipolar voltages tended also to be higher (3.35 ± 1.75 vs. 3.79 ± 1.77 mV, ns). Importantly, significant differences were found between mean unipolar voltages of the injected segments (9.62 ± 2.64 vs. 11.62 ± 3.50 mV, P = 0.014). There was also a clear tendency towards improvement of the bipolar measurements (3.69 ± 1.82 vs. 4.20 ± 2.06 mV), although this was statistically non-significant. Local loop shortening was similar for both time-points (6.20 ± 1.83 vs. 6.03 ± 3.22 for all segments and 5.40 ± 2.48 vs. 5.52 ± 3.87 for injected segments), and this was not statistically significant ( Figure 3) . The representative two-dimensional and three-dimensional electro-anatomical maps are presented in Figure 4 .
Safety and feasibility assessment
All patients were injected successfully. The mean injection procedure and follow-up mapping durations were 108 ± 12 min and 47 ± 9 min, respectively. The mean fluoroscopy time and radiation exposures were 22.1 ± 8. the follow-up mapping. The mean number of points acquired for baseline and follow-up maps were 149 ± 37 and 134 ± 19 points, respectively. There were no significant periprocedural complications regarding the access sites. One episode of ventricular fibrillation induced by injection catheter manipulations occurred at the end of the procedure (patient #11). The episode was successfully defibrillated and the patient remained stable. No other adverse events were observed for either initial and follow-up mapping, including hypotension, tamponade, or other arrhythmias ( Table 3) . No all-cause or cardiovascular deaths were documented during the 6-month follow-up.
One of 13 patients (patient #13) suffered from sustained ventricular tachycardia that required ICD intervention and hospitalization (after 2 months of the implantation procedure) and treatment with intravenous amiodarone. In addition, coronary angiography showed a significant stenosis of the first diagonal branch and this was treated with angioplasty and deployment of a drug-eluting stent. Ultimately, the patient stabilized on permanent amiodarone 100 mg/day. Additional assessments revealed that Cx-43 expression in the injected cells was negligible and comparable to that of the unmodified cells. For the remaining 12 patients the ICD interrogation performed at months 3 and 6 showed no significant ventricular arrhythmia within the tachycardia detection zone (>120 b.p.m., as indicated by ICD tachycardia monitoring option) and none of the patients required intervention for pacemaker-related complications (i.e. drop of R-wave amplitude, increased capture threshold, or lead impedance shift).
Discussion
The pilot clinical study presented is, to our best knowledge, the first research investigating the effect of transendocardial administration of MDS/PCs transfected with the Cx-43 gene in human subjects with advanced HF. The group studied comprised subjects with long-term LV systolic dysfunction secondary to ischaemic heart disease or dilated cardiomyopathy. All patients were on stable optimal medical therapy and treated with implantable devices. The transendocardial injection of Cx-43 MDS/PCs resulted in a significant improvement of exercise tolerance and capacity, as measured by a subjective NYHA classification and an objective cardiopulmonary exercise test after 6 months of the index procedure ( Table 2 ). These findings are mostly consistent with the previous studies of unmodified skeletal myoblasts used for myocardial regeneration. 6, 12, 16, 17 Although the first non-randomized research using the same delivery technique showed some improvement in exercise tolerance and LVEF at rest (between 24% and 32%) 12 and during stress echocardiography (40-46%), 13 the later studies were more cautious in their conclusions. The first of three randomized trials showed an improvement of LV diameters and viability, 15 while two recent studies did not confirm those findings but did find a tendency to improvement in exercise tolerance. 16, 17 It appears that the studies in which the cells were administered during cardiac surgery showed similar functional benefits. 25 -29 The present study consistently documented a trend towards better LV end-systolic and end-diastolic volumes as well as LVEF at 6 months after the implantation procedure. The present study used the percutaneous transcatheter approach. The use of an electro-anatomical navigation system for implantation of cells may confer a few advantages over 'blind' injections during cardiac surgery. The system clearly indicates the target areas within the scarred myocardium by voltage mapping and LLS. 30 It makes it possible to clearly differentiate the infarcted area from the viable myocardium and to identify the border zone, thus minimizing the risk of injecting the healthy myocardium and producing new re-entry substrates. 30 The assessment of unipolar voltage maps showed a significant increase in unipolar voltages measured in the injected segments of the left ventricle that may translate into improvement of myocardial viability and most probably reduction of total amount of infarcted myocardium. A similar effect was observed for unmodified myoblasts in previous studies.
BASELINE & INJECTION
15,30 Genetic modification did not weaken the regenerative potential of cells delivered. Furthermore, it can be assumed with high probability that repeated procedures could lead to better results in terms of improvement of viability and improvement of haemodynamic parameters, especially in patients with large left ventricles and extensive infarct-related scars. Subsequent procedures would target the border zones newly formed by the regeneration process. The major concern with this type of cells is associated with their potential to induce ventricular arrhythmias owing to the lack of newly formed gap junctions between the host cardiomyocytes and donor cells. 18, 31 The occurrence of ventricular arrhythmia with transendocardial cell delivery was up to 50% in the study subjects. 12 -14,17 They developed mostly non-sustained or sustained ventricular tachycardia treatable with amiodarone and requiring an ICD. The assessment of ventricular arrhythmias in HF subjects undergoing cell therapy is challenging as the aetiology of arrhythmia in this clinical setting is multifactorial. Patients with reduced EF are subjected to substantially higher risk of ventricular arrhythmias, including ventricular tachycardia and fibrillation, and sudden cardiac death. This is reflected in the clinical practice guidelines, which recommend the use of ICDs for primary prevention of sudden cardiac death. 24 Patients with advanced HF of ischaemic aetiology may additionally experience progression of atherosclerosis, new episodes of ischaemia and scar expansion. All these factors may provide new substrates to re-entrant circuits and support ventricular arrhythmias. Alternatively, injection of cells into the myocardium may form electrical islets promoting re-entrant arrhythmias, especially when injected into the healthy muscle. 32 It seems that the number of injected cells does not influence significantly the arrhythmic burden. In the MAGIC study 9 (transepicardial injection during cardiac surgery) no significant differences were observed regarding ventricular arrhythmia burden, time to arrhythmic episodes and time to other major cardiovascular adverse events between patients receiving low and high doses of myoblasts. In another study, MARVEL, 17 using catheter-based transendocardial approach, no significant differences were observed in adverse events (ventricular arrhythmias) between subjects receiving 400 and 800 × 10 6 cells. The number of cells delivered in our study was comparable to other researches. 33 Our study patients treated with
Cx-43-positive MDS/PCs developed no ventricular arrhythmias (i.e. sustained ventricular tachycardia or fibrillation), as confirmed by interrogation of implantable devices (ICD or CRT implanted in all study subjects). This may result from improved electrical coupling of the injected Cx-43-modified cells and injured myocardium and thus better in-situ mechanical cooperation of both cell types. The preclinical trials documented enhanced electrical coupling between skeletal myoblasts modified to overexpress Cx-43 and and their lower arrhythmogenic potential. 21, 22 The human skeletal myoblasts transfected with Cx-43 gene were found to be useful for myocardial regeneration in mice. 23 In our study group, one patient with ischaemic HF suffered from sustained ventricular tachycardia that required an ICD intervention. In this patient, the molecular analysis of cells showed that the expression of Cx-43 did not differ significantly from the unmodified MDS/PCs. In addition, coronary angiography showed a significant stenosis of a minor coronary branch that required angioplasty and could add to or create the proarrhythmic environment in this particular patient. 
Study limitations
This is a pilot clinical study and there was no control group. The study group comprised mostly males (one female), therefore gender differences could not be assessed. Although large number of cells were originally cultured from the harvested muscle biopsies, the method of Cx-43 gene transfection to myoblasts by electroporation resulted in loss of a considerable number of cells. This could be potentially overcome by the use of other genetic methods, such as viral vectors, or the patients may require repetitive therapies.
The population of implanted cells was non-homogeneous in terms of CD56 antigen expression. We observed that a majority of cells expressed surface CD56 marker (Beckmann Coulter, Fullerton, CA, USA). However, three different subgroups of patients could be distinguished: (i) a high percentage of CD56-positive cells (84 ± 1%); (ii) moderate expression CD56-positive cells (69 ± 11%), and (iii) a low proportion of CD56-positive cells (below 50%). Based on the literature, the expression of CD56 varies between individuals and can differ depending on the isoform of antibody used and therefore number measured by one specific test may not be actual. 34 The comparison of voltage measurements within the injected segments using the NOGA maps may be inaccurate, unlike the total voltages for the entire maps. The LV segments are determined automatically by the system, which sets them based on the indications of the point assigned to the apex and number of points acquired within the predefined segments. To optimize the map matching, we paid maximum attention to determine the LV apex (two fluoroscopic views were used: LAO 30 and RAO 30). In addition, the mapping procedure was performed by an experienced electrophysiologist in order to ensure that the entire ventricle was acquired. The post-processing included accurate selection of 'good' points that matched the predefined criteria (described in the Methods section).
As the participants were required to have ICD implanted, the study is missing delayed enhancement cardiac imaging.
Conclusions
Cellular therapy uniquely addresses the underlying mechanism of cardiac dysfunction in patients with HF (i.e. loss of functional cardiomyocytes and unfavourable remodelling). While being safe and feasible, transendocardial delivery of Cx-43-MDS/PCs can replenish the pool of damaged cardiac cells. Patients with advanced HF treated with Cx-43-MDS/PCs showed significantly better exercise capacity and a tendency towards reverse remodelling reflected by improved echocardiographic LV measures. In addition, the unipolar voltage mapping showed a significant increase in myocardial viability of the injected segments, which may result from the increased number of viable cells as well as angiogenesis. In our opinion the most important new information resulting from the study presented is that transfection of MDS/PCs with Cx-43 gene attenuated the proarrhythmic potential of skeletal myoblasts in the myocardial environment. It may result from improved electrical coupling of the injected cells and injured myocardium and thus better in-situ electro-mechanical cooperation of both cell types. This may switch our thinking about those genetically modified cells as a new 'old' therapeutic option in patients with advanced HF. Therefore, further studies involving more efficient genetic methods and larger number of patients are warranted.
Funding
The study was funded from the unrestricted national grant no. 
